- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00410774
Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery
A Phase I/II Study of Fixed-Dose Rate Gemcitabine and Bevacizumab for Postoperative Adjuvant Treatment of Patients With Resected Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine and bevacizumab after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase I/II trial is studying the side effects of gemcitabine and bevacizumab and to see how well they work in treating patients with pancreatic cancer that has been completely removed by surgery.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
Primary
- Determine the safety of adjuvant, fixed-dose rate gemcitabine hydrochloride and bevacizumab in patients with completely resected pancreatic cancer.
- Determine the 1-year disease-free survival rate in patients treated with this regimen.
Secondary
- Determine the 1- and 2-year overall survival rates in these patients.
- Determine the median disease-free survival rate in these patients.
- Determine the median overall survival rate in these patients.
OUTLINE: This is an open-label, non-randomized study.
Patients receive gemcitabine hydrochloride IV over 100 minutes followed by bevacizumab* IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
NOTE: *The first dose of bevacizumab is not administered until after 6 weeks have passed since surgery.
After completion of study therapy, patients are followed periodically for 18 months.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
San Francisco, California, Estados Unidos, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed adenocarcinoma of the pancreas
Completely resected disease
Underwent 1 of the following procedures 3-8 weeks ago:
- Standard pancreaticoduodenectomy (for tumors of the pancreatic head)
- Distal pancreatectomy (for tumors of the pancreatic tail)
No grossly positive surgical margins
- Positive microscopic margins allowed
- Nonmeasurable disease
- No known CNS disease
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after completion of study therapy
- CA 19-9 ≤ 2.5 times upper limit of normal (ULN)
- Absolute neutrophil count ≥ 1,500/mm³
- Hemoglobin ≥ 9 g/dL (transfusion or epoetin alfa allowed)
- Platelet count ≥ 100,000/mm³
- INR ≤ 1.5 (except in patients receiving full-dose warfarin)
- Bilirubin ≤ 2.0 mg/dL
- AST and ALT ≤ 2.5 times ULN
- Creatinine ≤ 2.0 mg/dL
- No clinically significant impairment of renal function
No postoperative complications, including any of the following:
- Wound dehiscence or infection
- Intra-abdominal abscess
- Pancreatic or biliary leak or fistula
- Grade 3 or 4 delayed hemorrhage (occurring > 5 days postoperatively)
- Bowel perforation
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abcess within the past 6 months
- No history of major psychiatric disorder or other chronic medical illness that, in the opinion of the treating physician, contraindicates use of the study drugs or renders the patient at high risk of treatment-related complications
- No other cancer within the past 5 years except basal cell or squamous cell skin cancer
No history of serious systemic disease, including any of the following:
- Myocardial infarction or unstable angina within the past 12 months
- New York Heart Association class II-IV congestive heart failure
Unstable symptomatic arrhythmia requiring medication
- Chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) allowed
- No history of stroke or transient ischemic attack
- No symptomatic peripheral vascular disease
- No significant vascular disease (e.g., aortic aneurysm, aortic dissection)
- No inadequately controlled hypertension (i.e., blood pressure > 150/100 mm Hg on antihypertensive medication)
- No prior hypertensive crisis or hypertensive encephalopathy
- No proteinuria (defined as urine protein:creatinine ratio ≥ 1.0 OR proteinuria ≥ 2+ by dipstick urinalysis OR protein > 1 g by 24-hour urine collection)
- No serious, nonhealing wound or ulcer
- No evidence of bleeding diathesis or coagulopathy
- No significant traumatic injury within the past 28 days
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior chemotherapy or radiotherapy for pancreatic cancer
- No prior systemic or investigational therapy for pancreatic cancer
- No major surgical procedure (except for resection of pancreatic cancer) or open biopsy within the past 28 days
- No fine-needle aspiration or core biopsy within the past 7 days
- No anticipated need for a major surgical procedure during study treatment
No concurrent newly prescribed nonsteroidal anti-inflammatory drugs (NSAIDs)
- Concurrent chronic-dose NSAIDs for analgesia are allowed
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
Safety of gemcitabine when administered with bevacizumab as assessed by NCI CTCAE v3.0
|
Disease-free survival rate at 1 year
|
Medidas de resultado secundarias
Medida de resultado |
---|
Overall survival rate at 1 and 2 years
|
Median disease-free survival rate at 1 and 2 years
|
Median overall survival rate at 1 and 2 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Silla de estudio: Andrew Ko, MD, University of California, San Francisco
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Enfermedades del sistema endocrino
- Neoplasias del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Neoplasias pancreáticas
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antineoplásicos inmunológicos
- Inhibidores de la angiogénesis
- Agentes moduladores de la angiogénesis
- Sustancias de crecimiento
- Inhibidores del crecimiento
- Gemcitabina
- Bevacizumab
Otros números de identificación del estudio
- CDR0000517330
- UCSF-06451
- UCSF-H12191-28980-01
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cancer de pancreas
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Xinhua Hospital, Shanghai Jiao Tong University...Aún no reclutandoCANCER DE PROSTATA | Biopsia de próstataPorcelana
Ensayos clínicos sobre terapia adyuvante
-
NeuroTronik Inc.DesconocidoInsuficiencia cardiaca | Insuficiencia cardíaca agudaParaguay
-
University of Roma La SapienzaTerminadoImplante dental fallido | Mucositis BucalItalia
-
NeuroTronik Inc.DesconocidoTerapia de estimulación autónoma del gasto cardíaco para la insuficiencia cardíaca aguda (COAST-AHF)Insuficiencia cardíaca agudaPanamá
-
Vyaire MedicalAún no reclutandoSíndrome de insuficiencia respiratoria del recién nacidoItalia
-
Boston Children's HospitalTerminadoEstrés Psicológico | Problema de aculturaciónEstados Unidos
-
Abbott Medical DevicesTerminadoFibrilación auricular paroxísticaAustralia, Alemania, Francia, Italia, Portugal, Reino Unido
-
Abbott Medical DevicesTerminadoFlutter auricular típicoEstados Unidos, Canadá
-
Abbott Medical DevicesTerminado
-
Northwestern UniversityNeuroneticsTerminadoDepresión | Ansiedad | Cáncer en remisión (cualquier tipo o etapa)Estados Unidos